Mergers and acquisitions… three words that bring giant and sometimes not-so-giant corporations together under one huge, carbon-footprint-inducing roof.
Here are a few high-profile deals that caught our eye, and one potential behemoth that could rear its head in the near future.
Yesterday, the French drugmaker agreed to buy the Belgian biotech company Ablynx for $4.8B.
Ablynx is it’s second high-profile biotech deal this month, after reeling in Bioverative for $11.6B.
There has been a relatively large uptick in biotech mergers in 2018 (with half as many this month as there were in all of 2017), and Sanofi’s leading the charge — making one of their most expensive purchases in 7 years.
Keurig Green Mountain, the company behind everyone’s favorite non-biodegradable coffee pods, has acquired the drink supergroup Dr. Pepper Snapple in a $21B pileup.
This makes it an even bigger supergroup, (dare we say megagroup?), now known as Keurig Dr. Pepper, expected to hit $11B in yearly revenue.
Dell technologies is considering a sale to VMware, the $60B cloud computing company that Dell is currently an 80% owner of.
This odd move is known as a “reverse merger,” and it gets slightly more odd: The acquisition would allow Dell to go public for the second time after re-privatizing back in 2013.
This deal is far from finalized, but if it goes through, it could help Dell’s investors — who backed their company move in 2013 — monetize their deal, and also pay down their $50B of debt.
Not to mention it would be the biggest deal in tech history.